Cyclohexylalanine-Containing α-Helical Amphipathic Peptide Targets Cardiolipin, Rescuing Mitochondrial Dysfunction in
Gwangsu Shin1, Soonsil Hyun1, Dongwoo Kim1
1Department of Chemistry & Education, Seoul National University, Seoul 08826, Korea.
Abstract:
Mitochondrial dysfunction is linked to degenerative diseases, resulting from cardiolipin (CL)-induced disruption of cristae structure in the inner mitochondrial membrane (IMM); therefore, preserving cristae and preventing CL remodeling offer effective strategies to maintain mitochondrial function. To identify reactive oxygen species (ROS)-blocking agents against mitochondrial dysfunction, a library of cyclohexylamine-containing cell-penetrating α-helical amphipathic "bundle" peptides were screened. Among these, CMP3013 is selectively bound to abnormal mitochondria, preserving the cristae structure impaired by mitochondria-damaging agents. With a stronger affinity for CL compared with other IMM lipid components, CMP3013 exhibited high selectivity. Consequently, it protected cristae, reduced ROS production, and enhanced adenosine triphosphate (ATP) generation. In mouse models of acute kidney injury, a 1 mg/kg dose of CMP3013 demonstrated remarkable efficacy, highlighting its potential as a therapeutic agent for mitochondrial dysfunction-related disorders. Overall, CMP3013 represents a promising agent for mitigating mitochondrial dysfunction and associated diseases.
Insights
A novel peptide, CMP3013, protects mitochondria by preserving inner mitochondrial membrane structure and reducing reactive oxygen species (ROS). This peptide shows promise for treating mitochondrial dysfunction and related degenerative diseases.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Mitochondrial dysfunction, often caused by cardiolipin (CL) remodeling and inner mitochondrial membrane (IMM) damage, is implicated in degenerative diseases.
- Preserving mitochondrial cristae structure and preventing CL remodeling are key therapeutic strategies.
Purpose of the Study:
- To identify novel agents that block reactive oxygen species (ROS) and mitigate mitochondrial dysfunction.
- To evaluate the therapeutic potential of a specific peptide, CMP3013, in models of mitochondrial damage.
Main Methods:
- Screening of cyclohexylamine-containing cell-penetrating peptides for ROS-blocking activity.
- Assessing peptide binding affinity to cardiolipin (CL) and other IMM lipids.
- Evaluating the effects of CMP3013 on mitochondrial cristae structure, ROS production, and ATP generation in vitro.
- Testing CMP3013 efficacy in a mouse model of acute kidney injury.
Main Results:
- CMP3013 selectively binds to abnormal mitochondria with high affinity for CL.
- CMP3013 preserves IMM cristae structure, reduces ROS production, and enhances ATP generation.
- A 1 mg/kg dose of CMP3013 showed significant efficacy in a mouse model of acute kidney injury.
Conclusions:
- CMP3013 is a promising therapeutic agent for mitochondrial dysfunction.
- The peptide's ability to protect cristae structure and reduce ROS offers a novel strategy for treating related disorders.
More Related Videos
07:14A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Published on: July 13, 2018
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
01:19Translocation of Proteins into the Mitochondria
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
01:39Mitochondrial Precursor Proteins
Most of the mitochondrial...
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...